|
|
|
|
|
|
|
M T W Th Fri |
|
18 September, 2026 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
China released a new five-year plan for biopharma today, outlining its vision for owning a significant portion of leading-edge innovation and expanding the international reach of its drugs. Drew Armstrong, Lei Lei Wu and Robert Postings have the details. |
|
|
|
Karen Weintraub |
Deputy Editor, Endpoints News
|
|
|
|
|
|
|
by Drew Armstrong, Robert Postings, Lei Lei Wu
|
Any doubts about China’s ambitions to be a major global competitor in biopharma are rapidly disappearing. On Friday, the Chinese government issuedthe latest
five-year... | |
|
|
|
|
|
|
by Andrew Dunn
|
When it made its much-hyped Mythos available back on July 1, Anthropic said the AI model was so powerful it couldn't allow the technology to... | |
|
|
|
|
|
|
by Max Gelman
|
The FDA granted full approval to a rare disease gene therapy from Ultragenyx on Thursday, giving the company a much-needed boost in an otherwise difficult... | |
|
|
|
|
|
|
by Kyle LaHucik
|
Electra Therapeutics became the 21st biotech of 2026 to go through with an IPO after pricing its $350 million Nasdaq debut on Thursday evening. The Bay... | |
|
|
|
 |
|
|
|
by Alex Hoffman, Lei Lei Wu, Kyle LaHucik
|
→ Legend Biotech has tapped Novartis executive Ingrid Zhangas its new CEO at a time when the company is seeking its next act. The... | |
|
|
|
|
|
